Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru

Objective To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was...

Descripción completa

Guardado en:
Autores principales: De-Los-Rios-Pinto, Abraham, Fernandez‐Guzman, Daniel, Soriano‐Moreno, David R., Sangster-Carrasco, Lucero, Morocho-Alburqueque, Noelia, Pinedo-Soria, Antony, Murrieta-Ruiz, Valentina, Diaz-Corrales, Angelica, Alave Rosas, Jorge Luis, Nieto-Gutierrez, Wendy, Gonzales-Zamora, Jose
Formato: Artículo
Lenguaje:inglés
Publicado: 2022
Materias:
Vaccine
Coronavirus
Clinical Trial
Associated Factors
Intention To Participate
Covid-19
Acceso en línea:Ver en el sistema de origen
Ver en el sistema de origen
Enlace permanente (DOI o Handle)
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Sumario:Objective To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. Results Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15-1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09-1.28) or jungle (RPa: 1.30; 95% CI: 1.15-1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06-1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17-1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29-1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). Conclusion There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.

Ejemplares similares